ストックスクリーナーアプリを入手
4.5712
4.10%
0.1812
前日終値:
$4.39
開ける：
$4.45
24時間の取引高:
375.08K
Relative Volume:
0.43
時価総額：
$438.74M
収益：
-
当期純損益:
$-238.77M
株価収益率:
-0.1705
EPS:
-26.808
ネットキャッシュフロー:
$-216.62M
1週間 パフォーマンス:
+6.28%
1か月 パフォーマンス:
+30.95%
6か月 パフォーマンス:
-12.28%
1年 パフォーマンス:
-64.49%
1日の値動き範囲:
$4.4422
$4.72
1週間の範囲:
$4.0911
$4.72
52週間の値動き範囲:
$2.7601
$13.11
Alumis Inc Stock (ALMS) Company Profile
ALMS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
4.57 | 456.10M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.62 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.07 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.26 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
648.57 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.00 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-25 | 開始されました | Wells Fargo | Overweight |
| 2025-06-10 | 再開されました | Guggenheim | Buy |
| 2025-01-30 | 開始されました | Oppenheimer | Outperform |
| 2024-10-31 | 開始されました | Robert W. Baird | Outperform |
| 2024-10-17 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 開始されました | Guggenheim | Buy |
| 2024-07-23 | 開始されました | Leerink Partners | Outperform |
| 2024-07-23 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Alumis Inc (ALMS) 最新ニュース
Alumis Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Alumis Inc. shares fall 1.36% intraday after reporting Q2 2025 financial results and merger with Acelyrin. - AInvest
Cantor Fitzgerald reiterates Overweight rating on Alumis stock amid post-merger decline - Investing.com Australia
Alumis Inc.: Strong Buy Rating Backed by Promising Drug Candidate and Strategic Positioning - TipRanks
Alumis Misses Q2 Revenue as Costs Jump - AOL.com
Alumis Q2 Revenue Down 5% YoY, Cash to Fund Ops into 2027 - AInvest
Alumis reports Q2 revenue $2.67M, consensus $2.43M - TipRanks
Alumis Misses Q2 Revenue as Costs Jump - The Motley Fool
Alumis Hits Major Milestone in Psoriasis Drug Development, Strengthens Pipeline with $486M War Chest - Stock Titan
While institutions invested in Alumis Inc. (NASDAQ:ALMS) benefited from last week's 4.1% gain, individual investors stood to gain the most - uk.finance.yahoo.com
Why Alumis Inc. stock attracts strong analyst attentionMassive Upside Stock List - thegnnews.com
Alumis Inc.'s (NASDAQ:ALMS) market cap touched US$444m last week, benefiting both retail investors who own 38% as well as institutions - simplywall.st
Alumis Inc. Concludes 2025 Annual Stockholders Meeting - The Globe and Mail
How strong is Alumis Inc. company’s balance sheetMassive stock growth - Jammu Links News
What is the dividend policy of Alumis Inc. stockGet alerts on high-potential stock breakouts - Jammu Links News
Should I hold or sell Alumis Inc. stock in 2025Build a portfolio that outperforms consistently - Jammu Links News
When is Alumis Inc. stock expected to show significant growthBuild a winning portfolio with smart picks - Jammu Links News
What drives Alumis Inc. stock priceInvest confidently with real-time data analysis - Jammu Links News
How volatile is Alumis Inc. stock compared to the marketInvest in stocks with strong fundamentals - Jammu Links News
What are analysts’ price targets for Alumis Inc. in the next 12 monthsCapitalize on trading strategies that deliver - Jammu Links News
What institutional investors are buying Alumis Inc. stockTurn volatility into profit opportunities - Jammu Links News
How many analysts rate Alumis Inc. as a “Buy”Build wealth steadily with expert advice - Jammu Links News
Confident Outlook on Acelyrin-Alumis Merger Amid Shareholder Opposition - TipRanks
How does Alumis Inc. compare to its industry peersDaily Trading Outlook With Proven Results - Jammu Links News
Is Alumis Inc. a growth stock or a value stockStock Strategy Tracker For Every Investor - Jammu Links News
What makes Alumis Inc. stock price move sharplyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Alumis (ALMS) Merges with ACELYRIN - Insider Monkey
Alumis Inc. Completes Merger with ACELYRIN, Boosts Balance Sheet and Advances Pipeline - AInvest
What is the risk reward ratio of investing in Alumis Inc. stockHarness the power of proven investment plans - jammulinksnews.com
Alumis Inc.: Promising Pipeline and Strategic Advancements Justify Buy Rating - TipRanks
How does Alumis Inc. generate profit in a changing economyPre Market Target Finder For 2025 - Jammu Links News
What markets is Alumis Inc. expanding into Is ELPW stock a good long term investment optionMaximize returns with smart investment plans - Jammu Links News
Is Alumis Inc. stock a good hedge against inflationBest Stocks for Capital Safety - metal.it
What analysts say about Alumis Inc. stockAccelerated capital growth - PrintWeekIndia
Alumis Inc. Stock Analysis and ForecastFree Investment Community - PrintWeekIndia
Alumis Inc.: Buy Rating Affirmed Amid Promising ESK-001 Developments and Strong Financial Projections - TipRanks
Alumis initiated with an Overweight at Wells Fargo - TipRanks
What institutions are buying Alumis Inc. stock nowExplosive wealth accumulation - Jammu Links News
Is Alumis Inc. a good long term investmentSuperior capital gains - PrintWeekIndia
Alumis Inc (ALMS) 財務データ
収益
当期純利益
現金流量
EPS
Alumis Inc (ALMS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Tananbaum James B. | Director |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Labs, LLC | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Labs, LLC | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Capital Management VI | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Capital Management VI | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| AKKARAJU SRINIVAS | Director |
May 05 '25 |
Buy |
4.67 |
160,370 |
749,676 |
3,586,788 |
| AKKARAJU SRINIVAS | Director |
May 02 '25 |
Buy |
4.55 |
159,920 |
727,636 |
3,426,418 |
| Colowick Alan | Director |
Apr 01 '25 |
Buy |
6.97 |
16,104 |
112,309 |
16,104 |
| Colowick Alan | Director |
Apr 02 '25 |
Buy |
7.49 |
2,300 |
17,235 |
18,404 |
| Babler Martin | President, CEO and Chairman |
Apr 01 '25 |
Buy |
6.44 |
15,650 |
100,733 |
106,454 |
0.48%
0.65%
大文字化:
|
ボリューム (24 時間):